Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Neostigmine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 14/20 | 0.86 |
| ▸ | BCHE | P06276 | 6/20 | 0.86 |
| ▸ | LMNA | P02545 | 4/20 | 0.86 |
| ▸ | MEN1 | O00255 | 1/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.83 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.83 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GLA | P06280 | 2/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Neostigmine SCHEMBL2028206 | 0.94 | ACHE (0.89) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL41902 | 0.93 | ACHE (0.85) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL8026154 | 0.93 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL29603805 | 0.93 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL34419 | 0.93 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL7105728 | 0.91 | ACHE (0.87) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL29618009 | 0.91 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL20425365 | 0.91 | ACHE (0.97) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL30029632 | 0.91 | ACHE (0.97) | ACHEBCHELMNAMEN1KMT2A | |
| Neostigmine SCHEMBL41128 | 0.91 | ACHE (1.00) | ACHEBCHELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | ACHE 18/4885BCHE 42/4885LMNA 3625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.